Partnering

Companies can partner with Novozymes Biopolymer to create innovative new products featuring the very highest standards of purity and safety. In fact, we are currently building a state-of-the-art cGMP facility and will be offering a full Q7A cGMP-validated process.

New dedicated cGMP HA facility
Drawing on our patented technology, we have designed a dedicated large-scale production facility, scheduled to start production of pharmaceutical-grade HA ingredients in 2011. Pilot process samples will be available already by early 2009.

First-mover advantages for our partners
To plan for capacity and to ensure efficient market entry, Novozymes Biopolymer is currently entering into strategic supply agreements with selected companies. This allows our partners to become “first movers” in the use of bHA. Moreover, they can reserve production capacity to meet long-term forecasts. Finally, our partners will be the first in the world to receive experimental samples and cGMP samples for clinical trials and/or bridging studies.

A roadmap you can rely on

Initiate                   Pilot process              Samples from          Q1: HyaCare 

                               samples                        cGMP facility            product launch

Learn more about how we can help you develop innovative new products
Find out how we can help optimize your production and increase profits